Baccel Bio, developing anticancer drugs(167,300 ↑29.99%)Shares jumped 15 times in two months. The clinical results of liver cancer treatments are attracting attention, and this is the influence of individual investors. The free increase announced on the 14th was also a boon.
On the 30th, Parkcelbio closed the transaction at 16,300 won, a 29.99% increase. The stock price surged despite the exclusion of the right to the right of free capital increase and ended at the upper limit for two consecutive days. The price is 15 times higher than the low of 10,225 won on October 20.
Due to the explosive rise in stock prices, Parkcelbio is evaluated as a symbol of communism in which the stock price surges after listing. On the bulletin board of the shareholders of the unlisted stock community, there are a lot of texts praying that the stock will become the’second Baxel Bio’. On the morning of the 30th, it became a hot topic enough to put the name on the Naver real-time search query list.
Parkcelbio has not received hot attention since the public offering. In September, the demand forecast competition rate was only 94.18 to 1, failing to make a hit. The public offering price was also set at 30,000 won, which is the lower end of the desired range. On September 22, the first day of listing, the transaction was closed at 21,300 won, down 29% from the public offering price. The reversal began in mid-October. The Hanyang Securities report, which explained the clinical results of a liver cancer treatment drug under development, received word of mouth. In the report, Oh Byung-yong, a researcher at Hanyang Securities, said, “The data on phase 1 clinical trials of’VAX-NK’, a liver cancer treatment drug, were remarkable.” Complete remission is a criterion for determining cancer treatment, and refers to a condition in which evidence of cancer has not been confirmed after treatment.
The grant was also a boon. On the 14th, Parkcell Bio announced a 100% free increase in allocation of one new stock per common stock. Shareholders who bought stocks by the 29th can receive new stocks, and the expected listing date is January 22nd. The number of shares from 7523,000 shares will increase to 15046,000 shares after a free increase. When new stocks are listed based on the closing price on the 30th, the market cap is expected to increase to KRW 2.5172 trillion.
Reporter Choi Ye-rin [email protected]
Ⓒ Hankyung.com prohibits unauthorized reproduction and redistribution